semaj83/ctmatch_classification huggingface dataset:
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Ulcer Within 24 hours of admission to Neurosurgical ICU after neurosurgery with ventilator support  Less than 18 y/o Pregnancy Not suitable for medication from NG route Had GI bleeding at admission to ICU
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-small Cell Lung Cancer Patient must be over the age of 18 years Pulmonary nodule with maximum diameter ≤ 5 cm Histological confirmation of primary NSCLC The following stage of NSCLC patients are eligible Stage I: T1 N0 M0 or T2 N0 M0 (Tumor size ≤ 5 cm) Stage II: T3 N0 M0 (Chest wall invasion only, Tumor size ≤ 5 cm) ECOG/Zubrod status of 0, 1 or 2 Thoracic surgery consultation should be obtained from a Board Certified Thoracic surgeon who in collaboration with a radiation oncologist should determine that the patient is not a surgical candidate In order to be considered medically inoperable, the patient must meet at least one major or a minimum of 2 minor as described below MAJOR  Excluding the primary cancer targeted for this treatment, the patient has a prior history of cancer (within the last 5 years) or concurrent cancer other than basal cell or squamous skin cancer Visible endobronchial lesion seen in the trachea, carina, major bronchus, lobar or segmental bronchus on bronchoscopy or microscopic disease detected in the trachea, carina, major bronchus, lobar or segmental bronchus The patient's weight exceeds the tolerances of the institution's imaging and CyberKnife platform/couch The patient has received thoracic radiation therapy in the same field as the planned treatment area in the past The patient has completed chemotherapy within less than 30 days of treatment T2: Tumor size > 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and ≤ 5 cm), T4 tumors. Presence of N1, N2 or N3 disease per previously described would be excluded Pancoast tumors would be excluded Current distant metastatic disease (M1) (preferably biopsy proven) The patient is a female with child-bearing potential who refuses to take a pregnancy test prior to treatment The patient is pregnant or a female who is nursing an infant
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Emphysema Pulmonary Disease, Chronic Obstructive for All Participants Able to read and write English At least 30 pack-year smoking history (the equivalent of smoking a pack a day for 30 years) Able to participate in the informed consent process Relatively stable clinical status for the past six weeks (i.e., no illness in the 6 weeks before study entry) for Participants with Emphysema Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II, III, or IV COPD, as determined by post-bronchodilator spirometry values OR More than minimal emphysema on an acceptable-quality chest CT scan for Participants without Emphysema GOLD class I COPD or GOLD class 0 (2005 classification), as determined post-bronchodilator spirometry values AND  Pregnant Prisoner Vulnerable populations Recent illness (defined as increased cough, sputum production, worsening malaise, or need for unscheduled physician visit in the 6 weeks prior to enrollment) Coexisting active chronic inflammatory or collagen vascular disease, immunodeficiency of any kind, non-cutaneous malignancy (melanoma is an exclusion), or previous organ transplant Congenital abnormalities of the lung or previous lung surgery Known active hepatitis B, hepatitis C, or HIV/AIDS (not prospectively evaluated) CT evidence of lung disease other than emphysema (including significant fibrosis, bronchiectasis, consolidation, or indeterminate nodules)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stomach Ulcer those recieved major abdominal surgery (estimated admission to sirgical ICU more than 7 days); give written consent and was randomized within 24 hours of admission  age less than 18 y/o; pregnant; allergy to famotidine or pantoprazole; have had GI bleeding
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Histologically confirmed non-small cell lung cancer Stage I or II disease (T1-3, N0, M0) T2 or T3 tumor ≤ 5 cm No T3 tumors involving the central chest or mediastinum (only chest wall involvement allowed) Tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, AND patient deemed "medically inoperable" Patients with FDG-avidity in mediastinal lymph nodes are eligible provided they are able to undergo mediastinoscopy to confirm N0 status ECOG performance status 0-2 Not pregnant or nursing Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment  No history of contrast allergy No psychological issues that would preclude the completion of study treatment No prior radiotherapy or chemotherapy No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar or mediastinal nodes that are either fludeoxyglucose F 18 [FDG]-avid or measure > 1 cm in short axis diameter on CT scan) No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree (carina, right and left main stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Unknown Primary Carcinoma Histologic or cytologic proven, non-resectable carcinoma of unknown primary (adenocarcinoma or non-differentiated carcinoma) Measurable tumor lesion(s) according to WHO PS 0 to 1 Paclitaxel/Carboplatin with or without Cetuximab in Adeno and Undifferentiated CUP (PACET-CUP) Signed written informed consent ≥ 18 years of age Effective contraception for both male and female subjects if the risk of conception exists Adequate bone marrow function Neutrophiles blood cell count (NBC) ≥ 1,5x109/L  Previous exposure to epidermal growth factor receptor-targeting therapy Previous chemotherapy except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy Investigational agents or participation in clinical trials within 30 days before treatment start in this study Clinically relevant coronary disease or myocardial infarction within 12 months before study entry Possibility of a curative local treatment (surgery and/or radiotherapy) Women with axillary node metastasis as predominant tumor site Women with peritoneal carcinomatosis as predominant tumor site Men < 50 years old with retroperitoneal or mediastinal lymph node +/
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Lung Cancer Diagnosis of suspected lung cancer or lung cancer  Inability to undergo therapy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Neoplasms Histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (> 20 cm from the incisors) or gastroesophageal junction are included No distant metastases (M0) Patients will be stratified by stage (clinical N0 versus clinical N1), and surgeon Patients with tumours within 3 cm distal spread into gastric cardia as detected by esophagogastroscopy Resectable mediastinal nodes are eligible No prior chemotherapy for this malignancy No prior radiotherapy that would overlap the field(s) treated in this study Patients with other malignancies are eligible only if > 5 years without evidence of disease or completely resected or treated non-melanoma skin cancer Age > 18 years and able to tolerate tri-modality therapy at the discretion of the treating thoracic surgeon, medical and radiation oncologists. Tumours must be resectable after assessment by the thoracic surgeon  Cancers of the cervical esophagus (< 20 cm are excluded) Tumours that have > 3 cm of spread into cardia of the stomach are considered gastric cancers and are ineligible Patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy ) proven metastatic supraclavicular nodes are ineligible Patients with biopsy proven metastatic celiac nodes are ineligible
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.5-20.0,  Neuroblastoma Brain Tumors Solid Tumors Histologically or cytologically confirmed neuroblastoma, brain tumor or other solid tumor (at diagnosis) Relapsed or refractory tumors in which correct standard treatment approaches have failed No more than 2 lines of prior chemotherapy Measurable primary and/or metastatic disease on CT/MRI at least one bi-dimensionally measurable lesion For patients with neuroblastoma, measurable disease will be defined by the modified International Neuroblastoma Staging System (Brodeur et al.1993) completed with MIBG scoring Age at 6 months to ≤ 20 years Lansky play score ≥ 70% or ECOG performance status ≤ 1 Life expectancy ≥ 3 months Adequate organ function Adequate haematological function: haemoglobin ≥ 80 g/l, neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L; in case of bone marrow disease: neutrophils ≥ 0.5 x 109/l and platelets ≥ 75 x 109/l  Concurrent administration of any other anti-tumour therapy Serious concomitant systemic disorder (for example, active infection including HIV or cardiac disease) that in the opinion of the investigator, would compromise the patient's ability to complete the study History of allergic reaction to the compounds or their solvents History of allergic reaction to Dacarbazine (DITC) Galactosemia, Glucose-galactose malabsorption or lactase deficiency Pregnant or breast feeding young women Presence of symptomatic brain metastases in patients with solid non-CNS tumors
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pulmonary Nodule, Solitary Multiple Pulmonary Nodules Scheduled for chest CT as part of their needed medical care If available, individuals who have had previous imaging to suggest they fulfill the needs of the study years of age, or older In good enough physical condition to stand motionless and hold their breath during the image acquisition procedures  Children under 18 years of age Women who are pregnant or who suspect they may be pregnant Individuals who on previous imaging are shown to have objects in or around the lungs that might produce substantial artifacts that would obscure pulmonary nodules Individuals who on recent imaging had active lung or pleural disease that would obscure pulmonary nodules Individuals with more than 5 pulmonary nodules between 5mm and 20mm in diameter in either right or left lung Individuals suspected to have more than 15 total nodules between 3mm and 20mm. NOTE that up to 20 nodules between 3mm and 20mm will be allowed in the final study sample
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Pneumonia Subject's parent or legal guardian, is able and willing to read the Informed Consent, understands the Informed Consent, and provides written Informed Consent for the subject; if the minor child is in fact able to give consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian Boy or girl in the age range of 3-18 years Patient presented with acute respiratory complaints, acute cough, onset of shortness of breath, or fever Patient referred by ED physician and presented for CXR  Body habitus or skin condition that might prevent the placement of the sound sensors on the back (e.g. severe scoliosis, kyphosis, chest wall deformation, skin lesion on the back or compression fracture) Potentially contagious skin lesion on the back Subject has had lung surgery Subject was prescribed the CXR for monitoring or follow up of a lung condition that pre-existed the current, acute symptoms
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Lung Cancer Patients will be evaluated for using the following All newly diagnosed patients with small lung nodules < 1cm that require excision with no history of prior ipsilateral thoracotomy The nodules must be located in parts of the lung that are amenable to thoracoscopic wedge excision of the nodules.The external surface of the lesion must be at least 2 cm from the major pulmonary arteries, veins, and main bronchi to allow safe and adequate thoracoscopic excision of the lesion Patients must be mentally competent to give written, informed consent Patients must be capable of independently completing standard English-language QOL instruments  Patients will be excluded from the trial if they do not consent to participate in the study, or if the radiologist and surgeon agree that the nodule is located too centrally to be safely excised using thoracoscopic wedge techniques Patients with more than three nodules will be excluded from the study Patients with a positive diagnosis of non-small cell lung cancer obtained from sputum cytology, bronchoscopy, or CT guided needle biopsy will be excluded from the study If the patient is excluded, he/she will receive the current standard treatment, which may needle biopsy, continued observation of the nodule at three to six monthly intervals, or excisional surgery (thoracoscopy or open thoracotomy)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Lung Abscess Adult 18-85 years of age Patients referred to pulmonologists, oncologists, or thoracic surgeons for the evaluation of peripheral lung nodules found on CT scan Repeat CT scans, biopsy or surgical excision are clinically indicated to determine the etiology of the nodule One or more lung nodules must be between 8 mm and 30 mm in the greatest diameter Patients must be fully informed of the investigational nature of the procedure and sign an informed consent  Lung nodules or masses greater than 30 mm in the greatest dimention Lung nodules that have solid calification Lung nodules or masses with CT evidence of partial or complete obstruciton of a lobar bronshus, mainstem bronchus or the trachea No prior cancer with the exception of non-melanoma skin cancer Life expectany of < t months Any indifidual who does not give oral and written consent for participation -
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Schizophrenia, Undifferentiated Type For patients Men and women, right handed, 18 to 45 years Having given their written informed consent Presenting a diagnosis of schizophrenia made by DMS IV, hospitalized or followed regularly in a hospital proper, and whose symptoms are stable for at least 6 weeks, at the discretion of the psychiatrist Receiving antipsychotic treatment (risperidone or aripiprazole) monotherapy stable (treatment and dose) for at least than 6 weeks Showing no contra-indication for fMRI Patients whose physical examination is unremarkable clinically significant Patients without serious somatic pathology Affiliated to a social security system For women of childbearing potential, an appropriate contraception is mandatory and an negative pregnancy test  For patients Patients in menstruation without effective contraception (oral, intramuscular hormonal, intrauterine device, or surgical) Patients who are pregnant or breastfeeding Patients not meeting for schizophrenia according to DSM IV or those with resistant schizophrenia (Kane criteria) Introducing a somatic disease or serious neurological, particularly Parkinson's disease, epilepsy, tardive dyskinesia and disabling cardiovascular disease, liver or kidney disease Presenting a contra-indication to MRI Having a history of alcoholism or drug addiction during the past year Participating in another clinical trial or are in a period of from a previous protocol Patients likely to have behavioral self aggression from the trial investigators During the study
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Lung Cancer Chronic Obstructive Airway Disease age 18-80 competent confirmed lung cancer  history of other cancers
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solitary Pulmonary Nodule Age> 18 years in patients with solitary pulmonary nodule who had percutaneous needle biopsy for diagnosis of lung nodule  patients who do not agree the study enrollment
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Patients undergoing elective, open and thoracoscopic thoracic surgery for any indication  Age < 18 years old Inability to consent for the study Chest wall anatomy precluding SATS Inability to sit upright